Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OZILTUS safely and effectively. See full prescribing information for OZILTUS. OZILTUS® (denosumab-mobz) injection, for subcutaneous use Initial U.S. Approval: 2010 OZILTUS (denosumab-mobz) is biosimilar* to XGEVA ® (denosumab)
Medication labelWhy this: Advisory · dailymed-prescription
Oziltus is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Oziltus is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials (14.2)]. Oziltus is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
- generic_name
- denosumab-mobz
- product_names
- denosumab-mobz
- ndc
- 70121-2701, 70121-2701-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en